Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$235.43 USD

235.43
607,131

-3.37 (-1.41%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $235.71 +0.28 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Myriad Genetics (MYGN) Expands Pharma Services With New Pact

Myriad Genetics (MYGN) will market the Personalis ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its pharmaceutical partners with a new collaboration.

Medtronic's (MDT) Symplicity Spyral RDN System Gets FDA Boost

Medtronic (MDT) receives the FDA approval for Symplicity blood pressure procedure for the treatment of hypertension.

Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics

Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.

Nemaura (NMRD) to Expand in UK With Metabolic Health Program

The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.

Neogen's (NEOG) Innovation Aids, Currency Headwind Stays

Neogen (NEOG) is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets.

Charles River (CRL) Widens CliniPrime GMP Suite With New Launch

Charles River (CRL) brings CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.

Paragon 28 (FNA) New Staple System Expands Ankle Device Line

Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.

Omnicell's (OMCL) Portfolio Expansion Aids Amid Macro Woes

Omnicell (OMCL) accelerates its shift to cloud-based solutions and tech-enabled services through the launch of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) due to its technology and innovative solutions.

Illumina (ILMN) Launches Initiative on Pathogen Sequencing

Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Prestige Consumer's (PBH) Brand Building, Innovation Aid Growth

Prestige Consumer's (PBH) long-term brand-building efforts, efficient marketing, channel development and innovation help the company to continually hold a leading market share position.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.

IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis

IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.

3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.

Surging Earnings Estimates Signal Upside for Insulet (PODD) Stock

Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

How to Find Strong Buy Medical Stocks Using the Zacks Rank

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth Today

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Sweta Killa headshot

5 Stocks That Powered S&P 500 ETF Last Week

After entering correction territory in the last week of October, the S&P 500 Index staged a solid comeback in the first week of November.